Art. -Nr.: HY-N2913

Ayanin

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Ayanin is a bioflavonoid isolated from Psychotria serpens. Ayanin is a non-selective phosphodiesterase_1-4 inhibitor and can be used for the study of respiratory disease,such as allergic asthma et al.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.18%
CAS. Nr.: 572-32-7
Formel: C₁₈H₁₆O₇
Molecular Weight:344.32

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ayanin Chemical Structure

CAS. Nr.: 572-32-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

PDE2A

PDE4

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	50 μM Compound: 16	Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay	[PMID: 21354800]
A2780 ADR	IC₅₀	9.4 μM Compound: 16	Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay	[PMID: 21354800]
A549	IC₅₀	20.79 μM Compound: 6a	Anticancer activity against human A549 cells by HTS assay Anticancer activity against human A549 cells by HTS assay	[PMID: 25139569]
BV-2	IC₅₀	25.1 μM Compound: 95; 105	Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 37683361]
Calu-1	IC₅₀	>50 μM Compound: 6a	Anticancer activity against human Calu1 cells by HTS assay Anticancer activity against human Calu1 cells by HTS assay	[PMID: 25139569]
HeLa	IC₅₀	19.47 μM Compound: 6a	Anticancer activity against human HeLa cells by HTS assay Anticancer activity against human HeLa cells by HTS assay	[PMID: 25139569]
HEp-2	IC₅₀	6.1 μM Compound: 16	Antiviral activity against RSV A2 infected in human HEp-2 cells assessed as reduction in viral plaque formation cells pretreated with compound for 15 mins followed by viral infection for 2.5 hrs and followed by incubation in CO2 incubator for 3 days by cr Antiviral activity against RSV A2 infected in human HEp-2 cells assessed as reduction in viral plaque formation cells pretreated with compound for 15 mins followed by viral infection for 2.5 hrs and followed by incubation in CO2 incubator for 3 days by cr	[PMID: 36749598]
HOP-62	IC₅₀	20.06 μM Compound: 6a	Anticancer activity against human HOP62 cells by HTS assay Anticancer activity against human HOP62 cells by HTS assay	[PMID: 25139569]
J774.A1	IC₅₀	17.8 μM Compound: 95; 105	Anti-inflammatory activity in mouse J774.A1 cells assessed as suppression of LPS-induced IL-6 production by ELISA analysis Anti-inflammatory activity in mouse J774.A1 cells assessed as suppression of LPS-induced IL-6 production by ELISA analysis	[PMID: 37683361]
LOX IMVI	IC₅₀	45.97 μM Compound: 6a	Anticancer activity against human LOXIMVI cells by HTS assay Anticancer activity against human LOXIMVI cells by HTS assay	[PMID: 25139569]
M14	IC₅₀	37.07 μM Compound: 6a	Anticancer activity against human M14 cells by HTS assay Anticancer activity against human M14 cells by HTS assay	[PMID: 25139569]
MCF7	IC₅₀	0.68 μM Compound: 16	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	IC₅₀	0.46 μM Compound: 16	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	IC₅₀	13 μM Compound: 16	Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry	[PMID: 21354800]
NCI-H1299	IC₅₀	>50 μM Compound: 6a	Anticancer activity against human H1299 cells by HTS assay Anticancer activity against human H1299 cells by HTS assay	[PMID: 25139569]
NCI-H157	IC₅₀	18.64 μM Compound: 6a	Anticancer activity against human NCI-H157 cells by HTS assay Anticancer activity against human NCI-H157 cells by HTS assay	[PMID: 25139569]
NCI-H1792	IC₅₀	>50 μM Compound: 6a	Anticancer activity against human NCI-H1792 cells by HTS assay Anticancer activity against human NCI-H1792 cells by HTS assay	[PMID: 25139569]
NCI-H1944	IC₅₀	21.92 μM Compound: 6a	Anticancer activity against human NCI-H1944 cells by HTS assay Anticancer activity against human NCI-H1944 cells by HTS assay	[PMID: 25139569]
NCI-H460	IC₅₀	12.79 μM Compound: 6a	Anticancer activity against human H460 cells by HTS assay Anticancer activity against human H460 cells by HTS assay	[PMID: 25139569]
NCI-H460	IC₅₀	5.7 μM Compound: 9	Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C Inhibition of ABCG2 expressed in human NCI-H460 cells assessed as inhibition of PhA accumulation after 2 to 20 hrs relative to fumitremorgin C	[PMID: 21275386]
NCI-H522	IC₅₀	20.21 μM Compound: 6a	Anticancer activity against human NCI-H522 cells by HTS assay Anticancer activity against human NCI-H522 cells by HTS assay	[PMID: 25139569]

In Vitro

Ayanin inhibits interleukin (IL)-4 production from purified basophils with an IC₅₀ value of 2.2 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 572-32-7
Appearance Solid
Molecular Weight 344.32
Formel C₁₈H₁₆O₇
Color White to yellow
SMILES

O=C1C(OC)=C(C2=CC=C(OC)C(O)=C2)OC3=CC(OC)=CC(O)=C13
Structure Classification
- Flavonoids
- Flavones
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Nat Biomed Eng

DeepDrugDiscovery identifies blood-brain barrier permeable autophagy enhancers for Alzheimer's disease. [Abstract]

2026 Apr 24. PMID: 42032039

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (726.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9043 mL

14.5214 mL

29.0428 mL

5 mM

0.5809 mL

2.9043 mL

5.8085 mL

10 mM

0.2904 mL

1.4521 mL

2.9043 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Fei-Peng Lee, et al. Ayanin, a Non-Selective Phosphodiesterase 1-4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness Without Affecting xylazine/ketamine-induced Anesthesia. Eur J Pharmacol. 2010 Jun 10;635(1-3):198-203. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9043 mL	14.5214 mL	29.0428 mL	72.6069 mL
	5 mM	0.5809 mL	2.9043 mL	5.8086 mL	14.5214 mL
	10 mM	0.2904 mL	1.4521 mL	2.9043 mL	7.2607 mL
	15 mM	0.1936 mL	0.9681 mL	1.9362 mL	4.8405 mL
	20 mM	0.1452 mL	0.7261 mL	1.4521 mL	3.6303 mL
	25 mM	0.1162 mL	0.5809 mL	1.1617 mL	2.9043 mL
	30 mM	0.0968 mL	0.4840 mL	0.9681 mL	2.4202 mL
	40 mM	0.0726 mL	0.3630 mL	0.7261 mL	1.8152 mL
	50 mM	0.0581 mL	0.2904 mL	0.5809 mL	1.4521 mL
	60 mM	0.0484 mL	0.2420 mL	0.4840 mL	1.2101 mL
	80 mM	0.0363 mL	0.1815 mL	0.3630 mL	0.9076 mL
	100 mM	0.0290 mL	0.1452 mL	0.2904 mL	0.7261 mL

Keywords

Ayanin

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ayanin

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) Ayanin

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ayanin

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) Ayanin

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ayanin Related Classifications

HY-N2913 Related Classifications